Differential pharmacokinetics of digoxin in elderly patients

被引:69
作者
Hanratty, CG
McGlinchey, P
Johnston, GD
Passmore, AP
机构
[1] Queens Univ Belfast, Dept Therapeut & Pharmacol, Belfast BT9 7BL, Antrim, North Ireland
[2] Queens Univ Belfast, Dept Care Elderly, Belfast BT9 7BL, Antrim, North Ireland
关键词
D O I
10.2165/00002512-200017050-00003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Digoxin remains one of the most commonly prescribed of all cardiac medications. The main indications for digoxin usage include atrial fibrillation and heart failure; both these conditions are more prevalent in older patients. Given the aging population and the increasing incidence of heart failure we would expect prescribing of digoxin to remain as frequent or to even increase in older patients. Older patients are also more likely to develop toxicity and diagnosis of digoxin toxicity can be difficult in this group. Numerous components contribute to the development of toxicity in older patients, ranging from aging-related changes in renal function or body mass to polypharmacy and possible interactions with digoxin. It is therefore important to understand how the pharmacokinetics of digoxin may be altered in the older population. Application of basic pharmacological principles may be helpful in anticipating these problems. This review describes the pharmacokinetics of digoxin, the changes in pharmacokinetics with increasing age and how concomitant disease states or drug interactions may affect the pharmacokinetics of digoxin. Greater knowledge about the causes and prevention of digoxin toxicity should further reduce the morbidity and mortality arising from digoxin toxicity, especially in the elderly population.
引用
收藏
页码:353 / 362
页数:10
相关论文
共 87 条
[1]   QUINIDINE REDUCES BILIARY CLEARANCE OF DIGOXIN IN MAN [J].
ANGELIN, B ;
ARVIDSSON, A ;
DAHLQVIST, R ;
HEDMAN, A ;
SCHENCKGUSTAFSSON, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1987, 17 (03) :262-265
[2]   AMIODARONE-INDUCED TORSADES-DE-POINTES - THE POSSIBLE FACILITATORY ROLE OF DIGOXIN [J].
BAJAJ, BP ;
BAIG, MW ;
PERRINS, EJ .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1991, 33 (02) :335-338
[3]   LACK OF EFFECTS OF DILTIAZEM ON DIGOXIN PHARMACOKINETICS [J].
BELTRAMI, TR ;
MAY, JJ ;
BERTINO, JS .
JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (05) :390-392
[4]   Digoxin-Macrolide drug interaction [J].
Bizjak, ED ;
Mauro, VF .
ANNALS OF PHARMACOTHERAPY, 1997, 31 (09) :1077-1079
[5]  
Borst S E, 1992, Cardiovasc Clin, V22, P161
[6]   Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion [J].
Boyd, RA ;
Stern, RH ;
Stewart, BH ;
Wu, XC ;
Reyner, EL ;
Zegarac, EA ;
Randinitis, EJ ;
Whitfield, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :91-98
[7]  
BROWN DD, 1976, CLIN PHARMACOL THER, V20, P395
[8]  
BROWN DD, 1979, DRUG METAB REV, V9, P107
[9]   INTESTINAL ABSORPTION OF DIGOXIN-3H IN RAT [J].
CALDWELL, JH ;
MARTIN, JF ;
DUTTA, S ;
GREENBERGER, NJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1969, 217 (06) :1747-+
[10]  
CASTLEDEN C M, 1977, Age and Ageing, V6, P138, DOI 10.1093/ageing/6.3.138